➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
Harvard Business School
Baxter
Johnson and Johnson
Moodys

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

Patent: 10,040,857

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,040,857
Title:Binding molecules specific for HER3 and uses thereof
Abstract: The present invention relates to antibodies and antigen binding fragments thereof that bind the extracellular domain of the HER3 receptor and inhibit various HER3 receptor related functions via ligand-dependent and/or ligand-independent mechanisms. Also provided are compositions with increased half-life. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER3 mediated signal transduction.
Inventor(s): Chowdhury; Partha S. (Gaithersburg, MD), Tice; David (Gaithersburg, MD), Xiao; Zhan (Boyds, MD), Steiner; Philipp (Washington, DC), Kinneer; Krista (Montgomery Village, MD), Rebelatto; Marlon (Gaithersburg, MD)
Assignee: MEDIMMUNE, LLC (Gaithersburg, MD)
Application Number:14/947,865
Patent Claims:see list of patent claims

Details for Patent 10,040,857

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial MEDIMMUNE, LLC (Gaithersburg, MD) 2031-11-23 RX Orphan search
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18   Start Trial MEDIMMUNE, LLC (Gaithersburg, MD) 2031-11-23 RX Orphan search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 001 2006-09-27   Start Trial MEDIMMUNE, LLC (Gaithersburg, MD) 2031-11-23 RX search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 002 2006-09-27   Start Trial MEDIMMUNE, LLC (Gaithersburg, MD) 2031-11-23 RX search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 003 2006-09-27   Start Trial MEDIMMUNE, LLC (Gaithersburg, MD) 2031-11-23 RX search
Genentech PERJETA pertuzumab VIAL; SINGLE-USE 125409 001 2012-06-08   Start Trial MEDIMMUNE, LLC (Gaithersburg, MD) 2031-11-23 RX search
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28   Start Trial MEDIMMUNE, LLC (Gaithersburg, MD) 2031-11-23 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
Express Scripts
Medtronic
Mallinckrodt
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.